H.C. Wainwright raised the firm’s price target on Celcuity (CELC) to $50 from $27 and keeps a Buy rating on the shares. After Celcuity reported positive topline efficacy results from the wild-type cohort of the VIKTORIA-1 Phase 3 trial, the firm is adjusting its view of probability of a launch to 70% from 49.5%, driving the firm’s raised target.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CELC:
- Morning News Wrap-Up: Monday’s Biggest Stock Market Stories!
- Celcuity price target raised to $74 from $29 at Needham
- U.S. strikes EU trade deal, Samsung to make AI6 chips for Tesla: Morning Buzz
- Relay Therapeutics has positive read from Celcuity data, says Barclays
- Stifel expects Celcuity shares to move ‘meaningfully higher’ after data